BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 28651488)

  • 1. Thymidine kinase 1 expression in ovarian serous adenocarcinoma is superior to Ki-67: A new prognostic biomarker.
    Wang J; Liu Q; Zhou X; He Y; Guo Q; Shi Q; Eriksson S; Zhou J; He E; Skog S
    Tumour Biol; 2017 Jun; 39(6):1010428317706479. PubMed ID: 28651488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear TK1 expression is an independent prognostic factor for survival in pre-malignant and malignant lesions of the cervix.
    Chen G; He C; Li L; Lin A; Zheng X; He E; Skog S
    BMC Cancer; 2013 May; 13():249. PubMed ID: 23693054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of tissue protein expression levels of MIB-1 (Ki-67) in Danish ovarian cancer patients. From the 'MALOVA' ovarian cancer study.
    Heeran MC; Høgdall CK; Kjaer SK; Christensen L; Jensen A; Blaakaer J; Christensen IJ; Høgdall EV
    APMIS; 2013 Dec; 121(12):1177-86. PubMed ID: 23594232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thymidine kinase 1 is a better prognostic marker than Ki-67 for pT1 adenocarcinoma of the lung.
    Xu Y; Liu B; Shi QL; Huang PL; Zhou XJ; Ma HH; Lu ZF; Bo Y; Eriksson S; He E; Skog S
    Int J Clin Exp Med; 2014; 7(8):2120-8. PubMed ID: 25232396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Muscle-invasive bladder cancer is characterized by overexpression of thymidine kinase 1.
    Rausch S; Hennenlotter J; Teepe K; Kuehs U; Aufderklamm S; Bier S; Mischinger J; Gakis G; Stenzl A; Schwentner C; Todenhöfer T
    Urol Oncol; 2015 Oct; 33(10):426.e21-9. PubMed ID: 26231311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High thymidine kinase 1 (TK1) expression is a predictor of poor survival in patients with pT1 of lung adenocarcinoma.
    Xu Y; Shi QL; Ma H; Zhou H; Lu Z; Yu B; Zhou X; Eriksson S; He E; Skog S
    Tumour Biol; 2012 Apr; 33(2):475-83. PubMed ID: 22143937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological markers in pT1 and pT2 ovarian cancer with lymph node metastases.
    Concin N; Hefler L; van Bavel J; Mueller-Holzner E; Zeimet A; Daxenbichler G; Speiser P; Hacker N; Marth C
    Gynecol Oncol; 2003 Apr; 89(1):9-15. PubMed ID: 12694648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of cell proliferating genes in patients with non-small cell lung cancer by immunohistochemistry and cDNA profiling.
    Mao Y; Wu J; Skog S; Eriksson S; Zhao Y; Zhou J; He Q
    Oncol Rep; 2005 May; 13(5):837-46. PubMed ID: 15809747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Construction and utilization of the prognostic model of serous ovarian adenocarcinoma].
    Yang R; Feng J; Fang XZ; Bai F; Cheng YX; Liu C; Zhu W; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2006 Jul; 41(7):459-63. PubMed ID: 17083811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.
    Bagegni N; Thomas S; Liu N; Luo J; Hoog J; Northfelt DW; Goetz MP; Forero A; Bergqvist M; Karen J; Neumüller M; Suh EM; Guo Z; Vij K; Sanati S; Ellis M; Ma CX
    Breast Cancer Res; 2017 Nov; 19(1):123. PubMed ID: 29162134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Musashi-1 Expression is a Prognostic Factor in Ovarian Adenocarcinoma and Correlates with ALDH-1 Expression.
    Chen PX; Li QY; Yang Z
    Pathol Oncol Res; 2015 Sep; 21(4):1133-40. PubMed ID: 25971681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High α B-crystallin and p53 co-expression is associated with poor prognosis in ovarian cancer.
    Tan L; Sha L; Hou N; Zhang M; Ma Q; Shi C
    Biosci Rep; 2019 Jun; 39(6):. PubMed ID: 31152111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytosolic thymidine kinase is a specific histopathologic tumour marker for breast carcinomas.
    He Q; Mao Y; Wu J; Decker C; Merza M; Wang N; Eriksson S; Castro J; Skog S
    Int J Oncol; 2004 Oct; 25(4):945-53. PubMed ID: 15375544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SALL4 is a marker of poor prognosis in serous ovarian carcinoma promoting invasion and metastasis.
    Yang M; Xie X; Ding Y
    Oncol Rep; 2016 Mar; 35(3):1796-806. PubMed ID: 26750614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of c-kit and ki-67 expression on patients prognosis in advanced ovarian serous carcinoma.
    Khalifeh I; Munkarah AR; Schimp V; Morris R; Lawrence WD; Ali-Fehmi R
    Int J Gynecol Pathol; 2005 Jul; 24(3):228-34. PubMed ID: 15968197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the concordance between the stage of the disease and Ki-67 proliferation index in gastroenteropancreatic neuroendocrine tumors.
    Özaslan E; Demir S; Karaca H; Güven K
    Eur J Gastroenterol Hepatol; 2016 Jul; 28(7):836-41. PubMed ID: 26945127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinesin family member 14: an independent prognostic marker and potential therapeutic target for ovarian cancer.
    Thériault BL; Pajovic S; Bernardini MQ; Shaw PA; Gallie BL
    Int J Cancer; 2012 Apr; 130(8):1844-54. PubMed ID: 21618518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
    Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of proline, glutamic acid, leucine rich protein 1 (PELP1) in triple-negative breast cancer: a retrospective study on 129 cases.
    Zhang Y; Dai J; McNamara KM; Bai B; Shi M; Chan MS; Liu M; Sasano H; Wang X; Li X; Liu L; Ma Y; Cao S; Xing Y; Zhao B; Song Y; Wang L
    BMC Cancer; 2015 Oct; 15():699. PubMed ID: 26472563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) uptake by PET correlates with thymidine kinase 1 expression: static and kinetic analysis of (18)F-FLT PET studies in lung tumors.
    Brockenbrough JS; Souquet T; Morihara JK; Stern JE; Hawes SE; Rasey JS; Leblond A; Wiens LW; Feng Q; Grierson J; Vesselle H
    J Nucl Med; 2011 Aug; 52(8):1181-8. PubMed ID: 21764789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.